| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Accounting Officer | Interim CFO
1 company
Sullivan Christopher Ryan is a Chief Financial Officer at Avalo Therapeutics, Inc.. Recent SEC Form 4 filings include 4 buys and 4 sells.
Estimated insider holdings value: $281K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | AVTX Avalo Therapeutics, Inc. | Chief Financial Officer | Sell | 15,959 | $16.96 | $270,593.02 | -14.4% | - | - | |
| Jun 9, 2023 | AVTX Avalo Therapeutics, Inc. | Chief Financial Officer | Buy | 511 | $3.42 | $1,747.62 | +68.0% | -97.6% | -98.9% | |
| Dec 10, 2021 | AVTX Avalo Therapeutics, Inc. | Chief Accounting Officer | Buy | 955 | $1.57 | $1,499.35 | +11.9% | -61.9% | -76.6% | |
| Dec 10, 2020 | AVTX Avalo Therapeutics, Inc. | Interim CFO | Buy | 5,095 | $2.28 | $11,606.41 | +172.5% | - | - | |
| Jun 10, 2020 | AVTX Avalo Therapeutics, Inc. | Interim CFO | Buy | 2,954 | $2.28 | $6,729.21 | New | - | - |